Literature DB >> 7594664

Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children.

H Käyhty1, H Ahman, P R Rönnberg, R Tillikainen, J Eskola.   

Abstract

Sixty-two infants and 31 toddlers were vaccinated with the tetravalent pneumococcal conjugate vaccine PncOMPC consisting of the capsular polysaccharide of pneumococcal types 6B, 14, 19F, and 23F conjugated to the outer membrane protein complex of Neisseria meningitidis. Infants were vaccinated at 2, 4, and 6 months (group A) or at 4, 6, and 14 months (group B); toddlers were vaccinated at 24 or at 24 and 26 months of age. The IgG responses to the four pneumococcal polysaccharide types were measured by EIA. In infants, types 14 and 19F induced a significant response after the first dose and types 6B and 23F after the second dose. A clearcut booster response was seen to the booster dose given at 14 months, indicating immunologic priming by the primary series at 2-6 months of age. The responses of the toddlers to one or two doses of the vaccine were very similar to the responses in infants.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7594664     DOI: 10.1093/infdis/172.5.1273

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  32 in total

1.  B and T cell immunity in patients with lysinuric protein intolerance.

Authors:  M Lukkarinen; K Parto; O Ruuskanen; O Vainio; H Käyhty; R M Olander; O Simell
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

2.  Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae.

Authors:  M Anttila; M Voutilainen; V Jäntti; J Eskola; H Käyhty
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 3.  Conjugate vaccines.

Authors:  D Goldblatt
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

Review 4.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

5.  Specificities and opsonophagocytic activities of antibodies to pneumococcal capsular polysaccharides in sera of unimmunized young children.

Authors:  Anu Soininen; Maijastiina Karpala; Sirkka-Liisa Wahlman; Hannele Lehtonen; Helena Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

6.  Immune profile of asplenic patients following single or double vaccine administration: A longitudinal cross-sectional study.

Authors:  Sait Murat Doğan; Ahmet Aykas; Evrim Şefika Yücel; Gökalp Okut; Cenk Şimşek; Kürşat Çayhan; Baha Zengel; Adam Uslu
Journal:  Ulus Cerrahi Derg       Date:  2015-04-09

7.  Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial.

Authors:  Nina Ekström; Heidi Ahman; Jouko Verho; Jukka Jokinen; Merja Väkeväinen; Terhi Kilpi; Helena Käyhty
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

8.  Concentration and high avidity of pneumococcal antibodies persist at least 4 years after immunization with pneumococcal conjugate vaccine in infancy.

Authors:  Nina Ekström; Heidi Ahman; Arto Palmu; Sinikka Grönholm; Terhi Kilpi; Helena Käyhty
Journal:  Clin Vaccine Immunol       Date:  2013-05-08

9.  Assignment of immunoglobulin G1 and G2 concentrations to pneumococcal capsular polysaccharides 3, 6B, 14, 19F, and 23F in pneumococcal reference serum 89-SF.

Authors:  A Soininen; I Seppälä; T Wuorimaa; H Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  1998-07

10.  Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components.

Authors:  Ron Dagan; David Goldblatt; James R Maleckar; Mansour Yaïch; Juhani Eskola
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.